Developer docs
API playgroundTry for free, no card

Search company profiles

NextPharma Oy

Full company profile

uuid004yyuw

Namestring
NextPharma Oy
Legal namestring
NextPharma Oy
Websiteurl
nextpharma.fi
Company typeenum
Private
Founded yearstring
-
Descriptiontext

NextPharma Oy is a Finnish-incorporated Contract Development and Manufacturing Organization (CDMO) headquartered in Tampere that delivers pharmaceutical development, manufacturing, and packaging services to pharmaceutical companies, biotech innovators, and health-and-nutrition firms. The company operates nine specialized Centres of Excellence across five European countries — Germany, the United Kingdom, France, Finland, and Norway — each dedicated to specific drug-delivery formats: penicillins (Berlin), modified-release formulations and analytical services (Bielefeld), solids and clinical-trial supply plus cephalosporins (Göttingen), hormones and semi-solids (Waltrop), liquid-filled hard capsules (Edinburgh), liquids and suppositories (Limay), lipid-based formulations and softgels (Ploërmel), ophthalmics (Tampere), and chewable tablets (Asker). This format-by-site specialization is the core technical architecture of the business.

The company's service portfolio spans five integrated lines: Pharmaceutical Development (formulation, analytical development, process optimization), Clinical Trials Services (clinical-trial supply), Commercial Manufacturing & Packaging, Health & Nutrition (food-supplement CDMO), and Analytical & Microbiological Services. Revenue is generated through B2B contract manufacturing engagements on a quote-based, project-and-volume pricing model, with go-to-market executed via direct enterprise sales supplemented by participation in major industry trade shows (CPHI, Vitafoods, Outsourcing in Clinical Trials).

In October 2025 NextPharma divested its logistics arm to Cencora and appointed Ajeeth Enjeti as CEO succeeding Peter Burema, repositioning the business as a pure-play European CDMO. The company emphasizes regulatory compliance (GMP) for highly controlled categories including antibiotics and hormones, and positions speed, flexibility, and a one-global-team approach as primary value propositions for sponsor customers.

Short descriptiontext

NextPharma Oy is a Finnish-headquartered European CDMO operating nine specialized manufacturing facilities across Germany, the UK, France, Finland, and Norway, providing pharmaceutical development, manufacturing, and packaging services to biotech and pharmaceutical innovators.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, CDMO services, pharmaceutical development, clinical trial supply, analytical testing services
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

NextPharma generates revenue through providing contract development and manufacturing services to pharmaceutical and nutraceutical companies. Revenue comes from pharmaceutical development services, clinical trials supply services, commercial manufacturing and packaging, and analytical/microbiological testing services.

nextpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NextPharma Oy is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical development, clinical trial supply, commercial manufacturing and packaging, and analytical/microbiological services to biotech, pharmaceutical, and nutritional supplement companies. The company operates 9 Centres of Excellence across Europe (Germany, UK, France, Finland, Norway) specialising in multiple dosage forms including penicillins, cephalosporins, modified release, softgels, ophthalmics, hormones, chewable tablets, liquids, and suppositories. Services span early-stage drug development through to commercial supply, delivered under a one global team model with integrated quality control testing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

NextPharma is a Contract Development and Manufacturing Organization (CDMO) offering an integrated portfolio of pharmaceutical development and manufacturing services across Europe. The company provides five core service lines: Pharmaceutical Development (formulation and process support from early stages to manufacturing), Clinical Trials Services (supply chain for clinical studies), Commercial Manufacturing & Packaging (large-scale production), Health and Nutrition (food supplements CDMO services), and Analytical and Microbiological Services (quality control testing). These services are delivered through a network of ten Centres of Excellence located across Europe (Germany, UK, France, Norway, Finland), each specializing in specific dosage forms including penicillins, cephalosporins, modified release formulations, liquid-filled hard capsules, softgels, liquids, suppositories, hormones, semi-solids, ophthalmics, and chewable tablets. The company positions itself as a one global team partner with customers at the centre of everything they do, offering fast, flexible, and tailored solutions for markets worldwide.

Product and service5 records
1Pharmaceutical Development
CategoryPharmaceutical Development Services
Description

Expert CDMO support for drug development projects from early stages through to manufacturing, covering formulation, analytical development, and process optimisation for biotech and pharmaceutical companies.

2Clinical Trials Services
CategoryClinical Trial Supply Services
Description

Flexible and reliable clinical trials supply services for biotech and pharmaceutical companies conducting human trials, including supply chain and packaging support.

3Commercial Manufacturing & Packaging
CategoryCommercial Manufacturing and Packaging Services
Description

Contract manufacturing services for commercial pharmaceutical supply, covering solid dosage forms, liquids, and packaging solutions for biotech and pharmaceutical companies requiring commercial-scale production.

4Health and Nutrition
CategoryNutraceutical Contract Manufacturing Services
Description

European contract development and manufacturing services for food supplements and nutritional products, serving health and nutrition companies seeking a European-based manufacturing partner.

5Analytical and Microbiological Services
CategoryAnalytical and Quality Control Services
Description

Comprehensive analytical and microbiological testing services that support pharmaceutical development and manufacturing quality control, offered as part of NextPharma's integrated CDMO service portfolio.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeOthersAnnounced on2025-10-13
Description

NextPharma sold its logistics arm to Cencora as part of a strategic plan to position NextPharma as Europe's leading pure-play CDMO. This divestment represents a significant strategic realignment focusing on core pharmaceutical development and manufacturing services.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeDirect peer
Description

Swedish-headquartered pan-European CDMO with multiple manufacturing sites across Europe offering solid dose, sterile, semi-solid and inhalation capabilities. Competes head-to-head with NextPharma for biotech and pharma contract manufacturing contracts across the same European customer base.

TypeBroad incumbent
Description

Swiss-listed global CDMO leader with extensive small-molecule API, oral dosage and biologics manufacturing capabilities across Europe and the US. Represents the broad incumbent competitor for both API and drug product contracts that NextPharma targets.

3Fareva
TypeDirect peer
Description

French privately-held CDMO with broad European manufacturing footprint spanning sterile injectables, liquids, ointments, and active ingredients. Direct competitor for European pharmaceutical contract manufacturing contracts, particularly in liquid and semi-solid dosage forms where both companies overlap.

TypeDirect peer
Description

German-headquartered CDMO with comparable pan-European manufacturing footprint and similar specialization in solid dosage forms, softgel capsules, and antibiotic production, including dedicated penicillins facilities. Operates as a direct competitor for European pharma contract manufacturing contracts across multiple dosage formats.

TypeBroad incumbent
Description

Through its Patheon CDMO business, Thermo Fisher operates one of the largest global pharmaceutical contract manufacturing networks across APIs, oral solid dose, sterile fill-finish and biologics. Competes for the same enterprise pharma customers as NextPharma in commercial manufacturing.

TypeDirect peer
Description

Swiss-listed CDMO specializing in API manufacturing and finished dosage forms across European and US sites, including controlled substances and steroids. Competes with NextPharma in commercial manufacturing and packaging for both branded and generic pharma customers.

TypeDirect peer
Description

Northern Ireland-headquartered CDMO with integrated API development, formulation, clinical supply, commercial manufacturing and analytical services across UK and Ireland sites. Directly comparable service portfolio to NextPharma including similar packaging, CTS and QC capabilities.

TypeBroad incumbent
Description

China-headquartered global CDMO offering API development, manufacturing and drug product services with growing European footprint through STA Pharma. Represents the emerging global-scale competitor targeting biotech and pharma outsourcing contracts that NextPharma also serves.

TypeBroad incumbent
Description

One of the largest global CDMOs offering softgel, oral solid dose, biologics and sterile fill-finish across dozens of sites worldwide. Competes with NextPharma for European commercial manufacturing contracts but at much larger scale across broader dosage formats and geographies.

TypeDirect peer
Description

European CDMO spun out of Roche offering API synthesis, peptide/lipid manufacturing, oral solid dose and sterile injectables across multiple European sites. Directly competes with NextPharma in formulation, manufacturing services and specialized drug delivery formats for pharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NextPharma Oy

Pharmaceutical CDMO Servicesnextpharma.fi

NextPharma Oy is a Finnish-headquartered European CDMO operating nine specialized manufacturing facilities across Germany, the UK, France, Finland, and Norway, providing pharmaceutical development, manufacturing, and packaging services to biotech and pharmaceutical innovators.

What NextPharma Oy does

NextPharma Oy is a Finnish-incorporated Contract Development and Manufacturing Organization (CDMO) headquartered in Tampere that delivers pharmaceutical development, manufacturing, and packaging services to pharmaceutical companies, biotech innovators, and health-and-nutrition firms. The company operates nine specialized Centres of Excellence across five European countries — Germany, the United Kingdom, France, Finland, and Norway — each dedicated to specific drug-delivery formats: penicillins (Berlin), modified-release formulations and analytical services (Bielefeld), solids and clinical-trial supply plus cephalosporins (Göttingen), hormones and semi-solids (Waltrop), liquid-filled hard capsules (Edinburgh), liquids and suppositories (Limay), lipid-based formulations and softgels (Ploërmel), ophthalmics (Tampere), and chewable tablets (Asker). This format-by-site specialization is the core technical architecture of the business.

The company's service portfolio spans five integrated lines: Pharmaceutical Development (formulation, analytical development, process optimization), Clinical Trials Services (clinical-trial supply), Commercial Manufacturing & Packaging, Health & Nutrition (food-supplement CDMO), and Analytical & Microbiological Services. Revenue is generated through B2B contract manufacturing engagements on a quote-based, project-and-volume pricing model, with go-to-market executed via direct enterprise sales supplemented by participation in major industry trade shows (CPHI, Vitafoods, Outsourcing in Clinical Trials).

In October 2025 NextPharma divested its logistics arm to Cencora and appointed Ajeeth Enjeti as CEO succeeding Peter Burema, repositioning the business as a pure-play European CDMO. The company emphasizes regulatory compliance (GMP) for highly controlled categories including antibiotics and hormones, and positions speed, flexibility, and a one-global-team approach as primary value propositions for sponsor customers.

NextPharma Oy firmographics

Firmographics
Name
NextPharma Oy
Legal name
NextPharma Oy
Website
https://nextpharma.fi
Company type
Private
Operating status
Operating
Headcount range
51–100 employees
Short description
NextPharma Oy is a Finnish-headquartered European CDMO operating nine specialized manufacturing facilities across Germany, the UK, France, Finland, and Norway, providing pharmaceutical development, manufacturing, and packaging services to biotech and pharmaceutical innovators.
Ownership category
akta.pro rank

NextPharma Oy industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Contract pharmaceutical manufacturing
  • CDMO services
  • Pharmaceutical development
  • Clinical trial supply
  • Analytical testing services

Where NextPharma Oy is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices9 records

Markets served

NextPharma Oy business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: NextPharma generates revenue through providing contract development and manufacturing services to pharmaceutical and nutraceutical companies. Revenue comes from pharmaceutical development services, clinical trials supply services, commercial manufacturing and packaging, and analytical/microbiological testing services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NextPharma Oy product offering

Product offering

Core offering

NextPharma Oy is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical development, clinical trial supply, commercial manufacturing and packaging, and analytical/microbiological services to biotech, pharmaceutical, and nutritional supplement companies. The company operates 9 Centres of Excellence across Europe (Germany, UK, France, Finland, Norway) specialising in multiple dosage forms including penicillins, cephalosporins, modified release, softgels, ophthalmics, hormones, chewable tablets, liquids, and suppositories. Services span early-stage drug development through to commercial supply, delivered under a one global team model with integrated quality control testing.

Product overview

NextPharma is a Contract Development and Manufacturing Organization (CDMO) offering an integrated portfolio of pharmaceutical development and manufacturing services across Europe. The company provides five core service lines: Pharmaceutical Development (formulation and process support from early stages to manufacturing), Clinical Trials Services (supply chain for clinical studies), Commercial Manufacturing & Packaging (large-scale production), Health and Nutrition (food supplements CDMO services), and Analytical and Microbiological Services (quality control testing). These services are delivered through a network of ten Centres of Excellence located across Europe (Germany, UK, France, Norway, Finland), each specializing in specific dosage forms including penicillins, cephalosporins, modified release formulations, liquid-filled hard capsules, softgels, liquids, suppositories, hormones, semi-solids, ophthalmics, and chewable tablets. The company positions itself as a one global team partner with customers at the centre of everything they do, offering fast, flexible, and tailored solutions for markets worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Development Expert CDMO support for drug development projects from early stages through to manufacturing, covering formulation, analytical development, and process optimisation for biotech and pharmaceutical companies.
  • Clinical Trials Services Flexible and reliable clinical trials supply services for biotech and pharmaceutical companies conducting human trials, including supply chain and packaging support.
  • Commercial Manufacturing & Packaging Contract manufacturing services for commercial pharmaceutical supply, covering solid dosage forms, liquids, and packaging solutions for biotech and pharmaceutical companies requiring commercial-scale production.
  • Health and Nutrition European contract development and manufacturing services for food supplements and nutritional products, serving health and nutrition companies seeking a European-based manufacturing partner.
  • Analytical and Microbiological Services Comprehensive analytical and microbiological testing services that support pharmaceutical development and manufacturing quality control, offered as part of NextPharma's integrated CDMO service portfolio.

Companies that use NextPharma Oy

Customer profile

Segments2 records

Ideal customer profiles2 records

NextPharma Oy technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

NextPharma Oy partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CencoramajorOthers · 13 October 2025NextPharma sold its logistics arm to Cencora as part of a strategic plan to position NextPharma as Europe's leading pure-play CDMO. This divestment represents a significant strategic realignment focusing on core pharmaceutical development and manufacturing services.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

NextPharma Oy competitors and assessment

Company assessment

Direct peers

  • Recipharm: Swedish-headquartered pan-European CDMO with multiple manufacturing sites across Europe offering solid dose, sterile, semi-solid and inhalation capabilities. Competes head-to-head with NextPharma for biotech and pharma contract manufacturing contracts across the same European customer base.
  • Fareva: French privately-held CDMO with broad European manufacturing footprint spanning sterile injectables, liquids, ointments, and active ingredients. Direct competitor for European pharmaceutical contract manufacturing contracts, particularly in liquid and semi-solid dosage forms where both companies overlap.
  • Aenova Group: German-headquartered CDMO with comparable pan-European manufacturing footprint and similar specialization in solid dosage forms, softgel capsules, and antibiotic production, including dedicated penicillins facilities. Operates as a direct competitor for European pharma contract manufacturing contracts across multiple dosage formats.
  • Siegfried Holding: Swiss-listed CDMO specializing in API manufacturing and finished dosage forms across European and US sites, including controlled substances and steroids. Competes with NextPharma in commercial manufacturing and packaging for both branded and generic pharma customers.
  • Almac Group: Northern Ireland-headquartered CDMO with integrated API development, formulation, clinical supply, commercial manufacturing and analytical services across UK and Ireland sites. Directly comparable service portfolio to NextPharma including similar packaging, CTS and QC capabilities.
  • CordenPharma: European CDMO spun out of Roche offering API synthesis, peptide/lipid manufacturing, oral solid dose and sterile injectables across multiple European sites. Directly competes with NextPharma in formulation, manufacturing services and specialized drug delivery formats for pharma customers.

Broad incumbents

  • Lonza Group: Swiss-listed global CDMO leader with extensive small-molecule API, oral dosage and biologics manufacturing capabilities across Europe and the US. Represents the broad incumbent competitor for both API and drug product contracts that NextPharma targets.
  • Thermo Fisher Scientific (Patheon): Through its Patheon CDMO business, Thermo Fisher operates one of the largest global pharmaceutical contract manufacturing networks across APIs, oral solid dose, sterile fill-finish and biologics. Competes for the same enterprise pharma customers as NextPharma in commercial manufacturing.
  • WuXi STA (WuXi AppTec): China-headquartered global CDMO offering API development, manufacturing and drug product services with growing European footprint through STA Pharma. Represents the emerging global-scale competitor targeting biotech and pharma outsourcing contracts that NextPharma also serves.
  • Catalent (Novo Holdings): One of the largest global CDMOs offering softgel, oral solid dose, biologics and sterile fill-finish across dozens of sites worldwide. Competes with NextPharma for European commercial manufacturing contracts but at much larger scale across broader dosage formats and geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

NextPharma Oy social profiles

Digital presence

NextPharma Oy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NextPharma Oy leadership team

Management profile

Number of profiles

Profiles1 record

NextPharma Oy funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NextPharma Oy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NextPharma Oy

What does NextPharma Oy do?

NextPharma Oy is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical development, clinical trial supply, commercial manufacturing and packaging, and analytical/microbiological services to biotech, pharmaceutical, and nutritional supplement companies. The company operates 9 Centres of Excellence across Europe (Germany, UK, France, Finland, Norway) specialising in multiple dosage forms including penicillins, cephalosporins, modified release, softgels, ophthalmics, hormones, chewable tablets, liquids, and suppositories. Services span early-stage drug development through to commercial supply, delivered under a one global team model with integrated quality control testing.

Is NextPharma Oy a public or private company?

NextPharma Oy is a private company. It is classified as unknown and is currently operating.

When was NextPharma Oy founded?

NextPharma Oy was founded in -1. It employs 51 to 100 people.

Where is NextPharma Oy based?

NextPharma Oy is headquartered in Berlin, Germany, in the Europe region.

How does NextPharma Oy make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are NextPharma Oy's main competitors?

Direct peers on record are Recipharm, Fareva, Aenova Group, Siegfried Holding, Almac Group and CordenPharma. Broad incumbents are Lonza Group, Thermo Fisher Scientific (Patheon), WuXi STA (WuXi AppTec) and Catalent (Novo Holdings).

Does NextPharma Oy have an API?

No public API is recorded for NextPharma Oy.

What industry is NextPharma Oy in?

NextPharma Oy's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals